DE1814671C3 - Radioaktive Di-(fluoresceinyl)-quecksilberderivate - Google Patents
Radioaktive Di-(fluoresceinyl)-quecksilberderivateInfo
- Publication number
- DE1814671C3 DE1814671C3 DE19681814671 DE1814671A DE1814671C3 DE 1814671 C3 DE1814671 C3 DE 1814671C3 DE 19681814671 DE19681814671 DE 19681814671 DE 1814671 A DE1814671 A DE 1814671A DE 1814671 C3 DE1814671 C3 DE 1814671C3
- Authority
- DE
- Germany
- Prior art keywords
- mercury
- radioactive
- carried out
- fluoresceinyl
- hgo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000002285 radioactive effect Effects 0.000 title claims description 11
- 150000002730 mercury Chemical class 0.000 title claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052753 mercury Inorganic materials 0.000 description 15
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 13
- 159000000000 sodium salts Chemical class 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 210000003205 muscle Anatomy 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical class O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- QSHDDOUJBYECFT-NJFSPNSNSA-N mercury-203 Chemical compound [203Hg] QSHDDOUJBYECFT-NJFSPNSNSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 238000004816 paper chromatography Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 229940100892 mercury compound Drugs 0.000 description 2
- 150000002731 mercury compounds Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- -1 (3.5-Dimethyl-4-iodpyrazolyl) -methyl Chemical group 0.000 description 1
- YNBZQSXWRWAXMV-UHFFFAOYSA-N 2',7'-dibromo-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C(O)C=C1OC1=C2C=C(Br)C(O)=C1 YNBZQSXWRWAXMV-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- DSVUBXQDJGJGIC-UHFFFAOYSA-N 3',6'-dihydroxy-4',5'-diiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C(I)=C1OC1=C(I)C(O)=CC=C21 DSVUBXQDJGJGIC-UHFFFAOYSA-N 0.000 description 1
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000209202 Bromus secalinus Species 0.000 description 1
- 101100322245 Caenorhabditis elegans des-2 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/10—Mercury compounds
- C07F3/12—Aromatic substances containing mercury
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS45668 | 1968-01-19 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE1814671A1 DE1814671A1 (de) | 1969-10-02 |
| DE1814671B2 DE1814671B2 (de) | 1974-02-28 |
| DE1814671C3 true DE1814671C3 (de) | 1974-10-17 |
Family
ID=5336652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19681814671 Expired DE1814671C3 (de) | 1968-01-19 | 1968-12-14 | Radioaktive Di-(fluoresceinyl)-quecksilberderivate |
Country Status (8)
| Country | Link |
|---|---|
| BE (1) | BE725326A (enrdf_load_stackoverflow) |
| BR (1) | BR6805051D0 (enrdf_load_stackoverflow) |
| CH (1) | CH510054A (enrdf_load_stackoverflow) |
| DE (1) | DE1814671C3 (enrdf_load_stackoverflow) |
| ES (1) | ES362130A1 (enrdf_load_stackoverflow) |
| FR (1) | FR1601504A (enrdf_load_stackoverflow) |
| GB (1) | GB1220500A (enrdf_load_stackoverflow) |
| NL (1) | NL6900831A (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2892330T3 (es) * | 2017-02-08 | 2022-02-03 | Helmholtz Zentrum Dresden | Compuestos de Hg-197(m) estables in vivo, método para su producción y su uso en diagnóstico por medicina nuclear y terapia con endorradionúclidos (teranóstica) |
-
1968
- 1968-12-04 CH CH1810368A patent/CH510054A/de not_active IP Right Cessation
- 1968-12-06 GB GB5793468A patent/GB1220500A/en not_active Expired
- 1968-12-12 BE BE725326D patent/BE725326A/xx unknown
- 1968-12-14 DE DE19681814671 patent/DE1814671C3/de not_active Expired
- 1968-12-20 BR BR20505168A patent/BR6805051D0/pt unknown
- 1968-12-24 FR FR1601504D patent/FR1601504A/fr not_active Expired
-
1969
- 1969-01-04 ES ES362130A patent/ES362130A1/es not_active Expired
- 1969-01-17 NL NL6900831A patent/NL6900831A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NL6900831A (enrdf_load_stackoverflow) | 1969-07-22 |
| DE1814671B2 (de) | 1974-02-28 |
| DE1814671A1 (de) | 1969-10-02 |
| BR6805051D0 (pt) | 1973-01-16 |
| CH510054A (de) | 1971-07-15 |
| FR1601504A (enrdf_load_stackoverflow) | 1970-08-24 |
| GB1220500A (en) | 1971-01-27 |
| BE725326A (enrdf_load_stackoverflow) | 1969-05-16 |
| ES362130A1 (es) | 1971-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2538388C3 (de) | Verfahren zur Herstellung eines stabilen, nicht-radioaktiven Trägermaterials für mit radioaktiven Elementen markierte Diagnosemittel und seine Verwendung für mit Tc-99m-markierte Diagnosemittel | |
| DE69109235T2 (de) | Verfahren zur Herstellung einer radiopharmazeutischer Zubereitung. | |
| DE3032781A1 (de) | Verfahren zur selektiven ablagerung einer radiopharmazeutischen verbindung in einem zielgewebe oder -organ und verbindungen zur durchfuehrung des verfahrens | |
| DE2947500C2 (de) | Radiojodierte ω -Phenylfettsäuren, ihre Herstellung und deren Verwendung zur szintigraphischen Untersuchung des Herzmuskels und der Leber | |
| DE69002627T2 (de) | 99 m Tc (III) herzmuskelbildende Mittel, wirksam beim Menschen. | |
| DE1467703A1 (de) | Keimtoetende Reinigungsmittel | |
| DE1814671C3 (de) | Radioaktive Di-(fluoresceinyl)-quecksilberderivate | |
| CH619366A5 (enrdf_load_stackoverflow) | ||
| DE2431561C2 (de) | Cycloalkylphenoxycarbonsäuren, Verfahren zu ihrer Herstellung und Arzneimittel | |
| DE2419310C3 (de) | Verwendung von Tc-99m-Komplexen | |
| EP0019790B1 (de) | Technetium-99m-markierte Acetanilidoiminodiacetate zur Leberfunktionsdiagnostik und Verfahren zu ihrer Herstellung | |
| DE69117741T2 (de) | Neue vorangeordnete sechszähnige liganden verwendbar in röntgenologischen bildformenden wirkstoffen | |
| DE2145282C3 (de) | 1-(Jodhydroxyphenyl)-2-aminopropanderivate, Verfahren zu ihrer Herstellung und diagnostisches Mittel | |
| DE1593788C (de) | Verfahren zur Herstellung von radioaktiven Fluorescein-quecksilber-derivaten, die mit radioaktivem 197Hg oder 203Hg markiert sind | |
| DE2551480B2 (de) | Technetium-99m-markiertes Nierendiagnostikum und Verfahren zu seiner Herstellung | |
| DE1932231A1 (de) | Diagnostisches und therapeutisches Praeparat auf der Basis eines chelatgebundenen Radio-Nuclids | |
| DE3216026A1 (de) | Technetium(99m)-markiertes isonicotinsaeurehydrazid, verfahren zu dessen herstellung und ein pharmazeutisches mittel, das diese verbindung enthaelt | |
| DE3524004A1 (de) | Generator fuer kurzlebige radionuclide | |
| DE1593788B1 (de) | Verfahren zur Herstellung von radioaktiven Fluorescein-quecksilberderivaten,die mit radioaktivem 197 Hg oder 203Hg markiert sind | |
| DE2108528A1 (de) | Verfahren zur Herstellung von mit Indium 113m markiertem Humantransfernn | |
| DE2343607C3 (de) | Verfahren zur Herstellung von mit Technetium markierten Komplexverbindungen und leberspezifisches radioaktives Mittel | |
| DE69824147T2 (de) | Technetium-99m markierte Diäthylentriaminpentaessigsäure-Diester und Verfahren zu deren Herstellung | |
| DE1813151A1 (de) | Verfahren zur Herstellung von mit radioaktiven Quecksilberisotopen markierten Fluoresceinderivaten durch anreicherung des rohen Reaktionsgemisches | |
| DE678948C (de) | Kontrastmittel fuer die Sichtbarmachung des Urogenitalsystems durch Roentgenstrahlen | |
| DE2522224A1 (de) | Jodierte verbindungen, verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) |